Cargando…
Following the COVID-19 Experience, Many Patients with Type 1 Diabetes Wish to Use Telemedicine in a Hybrid Format
Background: The COVID-19 pandemic has brought to light both challenges and unique opportunities regarding type 1 diabetes (T1D) management, including the usage of telemedicine platforms. Methods: This study was conducted in a tertiary hospital diabetes clinic. All consecutive T1D patients during Mar...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583150/ https://www.ncbi.nlm.nih.gov/pubmed/34769826 http://dx.doi.org/10.3390/ijerph182111309 |
_version_ | 1784597147991146496 |
---|---|
author | Schiller, Tal Zornitzki, Taiba Ostrovsky, Viviana Sapojnik, Danielle Cohen, Lee Kunyavski, Tamila Knobler, Hilla Kirzhner, Alena |
author_facet | Schiller, Tal Zornitzki, Taiba Ostrovsky, Viviana Sapojnik, Danielle Cohen, Lee Kunyavski, Tamila Knobler, Hilla Kirzhner, Alena |
author_sort | Schiller, Tal |
collection | PubMed |
description | Background: The COVID-19 pandemic has brought to light both challenges and unique opportunities regarding type 1 diabetes (T1D) management, including the usage of telemedicine platforms. Methods: This study was conducted in a tertiary hospital diabetes clinic. All consecutive T1D patients during March and June 2021 were asked to fill out a structured anonymous questionnaire that aimed to determine their preference regarding continuous use of a virtual platform. Results: In total, 126 T1D patients answered the questionnaire, of whom 51% were under the age of 40, half were men, half used insulin pumps, and 69% used continuous glucose monitoring. During the pandemic, the exposure of patients to virtual visits has grown about twofold, from 29% to 53%. Of the respondents, 49% expressed an interest in future usage of a virtual platform, but most of them preferred use in a hybrid manner. We found an association between preference to use telemedicine in the future and younger age, previous virtual platform experience, and confidence in being able to download data. Conclusions: Our data demonstrate that the COVID-19 experience has led to a growing interest of T1D patients in using the hybrid format of telemedicine. However, we still need to better understand who will benefit most from this platform and assess its cost-effectiveness and organization. |
format | Online Article Text |
id | pubmed-8583150 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85831502021-11-12 Following the COVID-19 Experience, Many Patients with Type 1 Diabetes Wish to Use Telemedicine in a Hybrid Format Schiller, Tal Zornitzki, Taiba Ostrovsky, Viviana Sapojnik, Danielle Cohen, Lee Kunyavski, Tamila Knobler, Hilla Kirzhner, Alena Int J Environ Res Public Health Article Background: The COVID-19 pandemic has brought to light both challenges and unique opportunities regarding type 1 diabetes (T1D) management, including the usage of telemedicine platforms. Methods: This study was conducted in a tertiary hospital diabetes clinic. All consecutive T1D patients during March and June 2021 were asked to fill out a structured anonymous questionnaire that aimed to determine their preference regarding continuous use of a virtual platform. Results: In total, 126 T1D patients answered the questionnaire, of whom 51% were under the age of 40, half were men, half used insulin pumps, and 69% used continuous glucose monitoring. During the pandemic, the exposure of patients to virtual visits has grown about twofold, from 29% to 53%. Of the respondents, 49% expressed an interest in future usage of a virtual platform, but most of them preferred use in a hybrid manner. We found an association between preference to use telemedicine in the future and younger age, previous virtual platform experience, and confidence in being able to download data. Conclusions: Our data demonstrate that the COVID-19 experience has led to a growing interest of T1D patients in using the hybrid format of telemedicine. However, we still need to better understand who will benefit most from this platform and assess its cost-effectiveness and organization. MDPI 2021-10-28 /pmc/articles/PMC8583150/ /pubmed/34769826 http://dx.doi.org/10.3390/ijerph182111309 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Schiller, Tal Zornitzki, Taiba Ostrovsky, Viviana Sapojnik, Danielle Cohen, Lee Kunyavski, Tamila Knobler, Hilla Kirzhner, Alena Following the COVID-19 Experience, Many Patients with Type 1 Diabetes Wish to Use Telemedicine in a Hybrid Format |
title | Following the COVID-19 Experience, Many Patients with Type 1 Diabetes Wish to Use Telemedicine in a Hybrid Format |
title_full | Following the COVID-19 Experience, Many Patients with Type 1 Diabetes Wish to Use Telemedicine in a Hybrid Format |
title_fullStr | Following the COVID-19 Experience, Many Patients with Type 1 Diabetes Wish to Use Telemedicine in a Hybrid Format |
title_full_unstemmed | Following the COVID-19 Experience, Many Patients with Type 1 Diabetes Wish to Use Telemedicine in a Hybrid Format |
title_short | Following the COVID-19 Experience, Many Patients with Type 1 Diabetes Wish to Use Telemedicine in a Hybrid Format |
title_sort | following the covid-19 experience, many patients with type 1 diabetes wish to use telemedicine in a hybrid format |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583150/ https://www.ncbi.nlm.nih.gov/pubmed/34769826 http://dx.doi.org/10.3390/ijerph182111309 |
work_keys_str_mv | AT schillertal followingthecovid19experiencemanypatientswithtype1diabeteswishtousetelemedicineinahybridformat AT zornitzkitaiba followingthecovid19experiencemanypatientswithtype1diabeteswishtousetelemedicineinahybridformat AT ostrovskyviviana followingthecovid19experiencemanypatientswithtype1diabeteswishtousetelemedicineinahybridformat AT sapojnikdanielle followingthecovid19experiencemanypatientswithtype1diabeteswishtousetelemedicineinahybridformat AT cohenlee followingthecovid19experiencemanypatientswithtype1diabeteswishtousetelemedicineinahybridformat AT kunyavskitamila followingthecovid19experiencemanypatientswithtype1diabeteswishtousetelemedicineinahybridformat AT knoblerhilla followingthecovid19experiencemanypatientswithtype1diabeteswishtousetelemedicineinahybridformat AT kirzhneralena followingthecovid19experiencemanypatientswithtype1diabeteswishtousetelemedicineinahybridformat |